Key result
The primary cardiomyopathy of systemic sclerosis was associated with a greater long-term incidence of death or MACE (adjusted HR 2.01; 95% CI 1.03-3.92; P=0.041).
Why the study?
Cardiac disease in systemic sclerosis (SSc) can be primary or secondary, but the prevalence, CMR features, and prognostic implications of primary SSc cardiomyopathy are unknown.
Does the presence of primary cardiomyopathy of systemic sclerosis on CMR predict death or major adverse cardiac events in patients with systemic sclerosis?
Population
130 consecutive patients with SSc undergoing clinical CMR for suspected cardiac involvement
Comparison
Primary cardiomyopathy of SSc vs absence of primary cardiomyopathy of SSc
Design
Retrospective cohort study
Follow-up
Median 3.6 years
Authors
Loading...
May inform CMR-based risk stratification in SSc; leaves open whether detection alters management or outcomes.
Cohort (n=130)
Does the presence of primary cardiomyopathy of systemic sclerosis on CMR predict death or major adverse cardiac events in patients with systemic sclerosis?
Hazard Ratio: 2.01 (95% CI 1.03–3.92)
p-value: p=0.041
Primary cardiomyopathy of systemic sclerosis is present in 21% of SSc patients undergoing CMR and is independently associated with a twofold increased risk of death or major adverse cardiac events.
Chhikara et al. (2023) conducted a cohort in Systemic sclerosis (SSc) (n=130). Primary cardiomyopathy of SSc vs. Patients without primary cardiomyopathy of SSc was evaluated on Death or major adverse cardiac events (MACEs) (HR 2.01, 95% CI 1.03-3.92, p=0.041). The primary cardiomyopathy of systemic sclerosis was associated with a greater long-term incidence of death or MACE (adjusted HR 2.01; 95% CI 1.03-3.92; P=0.041).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: